

Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN

NCT07187908

Status	RECRUITING
Phase	Phase 2
Sponsor	Henan Cancer Hospital
Enrollment	1,076 participants

Key Eligibility Criteria

Inclusion (13)

- Willing to sign the informed consent form and be able to comply with the requirements of the protocol;
- Age 18 years old, < 75 years old;
- Patients with solid tumors confirmed by histopathology or cytology;
- Cohort 1 requires that the patient has not used G-CSF drugs during this chemotherapy treatment;
- Cohort 2 requires patients to suffer e3 grade ANC reduction after the first course of chemotherapy, and there still has the risk in the subsequent chemotherapy;
- ... and 8 more (see full listing online)

Exclusion (15)

- Uncontrolled infection within 72 hours prior to chemotherapy or receiving systemic antibiotic therapy;
- Pregnant or lactating women;
- Have received bone marrow transplantation or stem cell transplantation in the past;
- Have 2 or more kinds of primary malignant tumors at the same time; However, the following exceptions are: 1) malignant tumors that have complete response for at least 2 years prior to enrollment and do not require other treatment during the study period; 2) non-melanoma skin cancer or lentigo maligna that has been adequately treated and has no evidence of disease recurrence; 3) carcinoma in situ that has been adequately treated and has no evidence of disease recurrence;
- Psychiatric or brain metastases;
- ... and 10 more (see full listing online)

Locations (1 total)

The Henan cancer hospital, Zhengzhou, Henan, China